Home >> Research Area >>Proteases/Proteasome>>DPP-4>> Alogliptin Benzoate

Alogliptin Benzoate

DPP-4 inhibitor,selective and potent,antidiabetic drug CAS# 850649-62-6

Alogliptin Benzoate

Catalog No. BCC1341----Order now to get a substantial discount!

Product Name & Size Price Stock
Alogliptin Benzoate: 5mg $17 In Stock
Alogliptin Benzoate: 10mg Please Inquire In Stock
Alogliptin Benzoate: 20mg Please Inquire Please Inquire
Alogliptin Benzoate: 50mg Please Inquire Please Inquire
Alogliptin Benzoate: 100mg Please Inquire Please Inquire
Alogliptin Benzoate: 200mg Please Inquire Please Inquire
Alogliptin Benzoate: 500mg Please Inquire Please Inquire
Alogliptin Benzoate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Alogliptin Benzoate

Number of papers citing our products

Chemical structure

Alogliptin Benzoate

3D structure

Chemical Properties of Alogliptin Benzoate

Cas No. 850649-62-6 SDF Download SDF
PubChem ID 16088021 Appearance Powder
Formula C25H27N5O4 M.Wt 461.51
Type of Compound N/A Storage Desiccate at -20°C
Synonyms SYR 322
Solubility DMSO : 50 mg/mL (108.34 mM; Need ultrasonic)
Chemical Name 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile;benzoic acid
SMILES CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N.C1=CC=C(C=C1)C(=O)O
Standard InChIKey KEJICOXJTRHYAK-XFULWGLBSA-N
Standard InChI InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Alogliptin Benzoate

DescriptionAlogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with an IC50 value of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
TargetsDPP-4    
IC50<10 nM     

Alogliptin Benzoate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Alogliptin Benzoate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Alogliptin Benzoate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1668 mL 10.834 mL 21.668 mL 43.336 mL 54.17 mL
5 mM 0.4334 mL 2.1668 mL 4.3336 mL 8.6672 mL 10.834 mL
10 mM 0.2167 mL 1.0834 mL 2.1668 mL 4.3336 mL 5.417 mL
50 mM 0.0433 mL 0.2167 mL 0.4334 mL 0.8667 mL 1.0834 mL
100 mM 0.0217 mL 0.1083 mL 0.2167 mL 0.4334 mL 0.5417 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Alogliptin Benzoate

Alogliptin is a novel, highly selective and potent inhibitor of serine protease dipeptidylpeptidase-4 (DPP-4) with IC50 value of less than 10 nM [1].

Alogliptin has been reported to significantly reduce plasma DPP-4 activity and increase active GLP-1 levels in a dose-dependent manner in ob/ob mice. Besides, alogliptin after 4 weeks administration remarkably reduced non-fasting glycosylated hemoglobin, non-fasting plasma glucose and triglyceride levels, as well as siginificantly increased non-fasting plasma insulin and fasting pancreatic insulin content in ob/ob mice. Moreover, alogliptin treated ob/ob mice have shown the increase of early-phase insulin secretion and the decrease of plasma glucose AUC [2]

References:
[1] Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL 2nd. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300.
[2] Moritoh Y1, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32.

Featured Products
New Products
 

References on Alogliptin Benzoate

Alogliptin benzoate for management of type 2 diabetes.[Pubmed:25914541]

Vasc Health Risk Manag. 2015 Apr 10;11:229-43.

Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well tolerated because of their low risk of hypoglycemia and other adverse events. Moreover, with their potential to improve beta cell function, a core defect of type 2 diabetes, DPP-4 inhibitors are becoming a major component of treatment of type 2 diabetes. Alogliptin Benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. Once-daily administration of alogliptin as either monotherapy or combination therapy with other oral antidiabetic drugs or insulin has a potent glucose-lowering effect which is similar to that of other DPP-4 inhibitors, with a low risk of hypoglycemia and weight gain. The cardiovascular safety of this drug has been confirmed in a recent randomized controlled trial. This review summarizes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

Alogliptin benzoate for the treatment of type 2 diabetes.[Pubmed:24646052]

Expert Opin Pharmacother. 2014 Apr;15(6):851-63.

INTRODUCTION: Type 2 diabetes mellitus continues to be a global problem, placing an enormous burden on healthcare systems and resources. Effective treatment options to minimize the effects of hyperglycemia are essential. Most patients eventually need to take multiple drugs to maintain glycemic control, and many antidiabetic drugs are associated with adverse effects, such as hypoglycemia, weight gain or gastrointestinal effects. Dipeptidyl peptidase (DPP)-4 inhibitor is one of the newer classes of oral antidiabetic drug, and alogliptin is the most recently approved drug in this class. AREAS COVERED: This paper reviews the pharmacodynamic and pharmacokinetic properties of alogliptin and the results of clinical trials evaluating its efficacy at improving glycemic control in patients with type 2 diabetes both as monotherapy and in combination with other antidiabetic drugs. The drug's tolerability and safety profiles are also considered. EXPERT OPINION: Alogliptin is a DPP-4 inhibitor that can help in improving glycemic control in patients with type 2 diabetes, including the elderly. It is generally well tolerated and does not increase the risk of hypoglycemia or weight gain.

Degradation Kinetics Study of Alogliptin Benzoate in Alkaline Medium by Validated Stability-Indicating HPTLC Method.[Pubmed:27608919]

J AOAC Int. 2016 Nov 1;99(6):1505-1512.

A rapid, sensitive, and stability-indicating high-performance thin-layer chromatographic method was developed and validated to study degradation kinetics of Alogliptin Benzoate (ALG) in an alkaline medium. ALG was degraded under acidic, alkaline, oxidative, and thermal stress conditions. The degraded samples were chromatographed on silica gel 60F254-TLC plates, developed using a quaternary-solvent system (chloroform-methanol-ethyl acetate-triethyl amine, 9+1+1+0.5, v/v/v/v), and scanned at 278 nm. The developed method was validated per International Conference on Harmonization guidelines using validation parameters such as specificity, linearity and range, precision, accuracy, LOD, and LOQ. The linearity range for ALG was 100-500 ng/band (correlation coefficient = 0.9997) with an average recovery of 99.47%. The LOD and LOQ for ALG were 9.8 and 32.7 ng/band, respectively. The developed method was successfully applied for the quantitative estimation of ALG in its synthetic mixture with common excipients. Degradation kinetics of ALG in an alkaline medium was studied by degrading it under three different temperatures and three different concentrations of alkali. Degradation of ALG in the alkaline medium was found to follow first-order kinetics. Contour plots have been generated to predict degradation rate constant, half-life, and shelf life of ALG in various combinations of temperature and concentration of alkali using Design Expert software.

Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques.[Pubmed:27281581]

J Pharm Biomed Anal. 2016 Sep 5;128:253-263.

A highly specific and efficient LC-QTOF mass spectrometric method was developed for the separation and characterization of process related substances and the major degradation products in Alogliptin Benzoate and its tablets. The separation was performed on Phenomenex Gemini-NX C18 column (250mmx4.6mm, 5mum) using 0.2% formic acid-0.2% ammonium acetate in water as mobile phase A, acetonitrile and methanol (60:40, v/v) as mobile phase B in linear gradient elution mode. Forced degradation studies were also conducted under ICH prescribed stress conditions. Alogliptin Benzoate and its tablets were tending to degrade under acid, alkaline, oxidative and thermal stresses, while relatively stable to photolytic stress. A total of seven related substances were detected and characterized through liquid chromatography-high resolution QTOF mass spectrometry techniques, including process related substances and degradation products, and two of them were further synthesized and characterized by NMR spectroscopy. Based on the related substances elucidation and the plausible formation mechanisms, efficient approaches were proposed to reduce or eliminate related substances, and in consequence the quality of Alogliptin Benzoate and its tablets have been promoted obviously. Therefore, the impurity profiles obtained are critical to the quality control and manufacturing processes optimization and monitoring of Alogliptin Benzoate and its tablets.

Description

Alogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

Keywords:

Alogliptin Benzoate,850649-62-6,SYR 322,Natural Products,DPP-4, buy Alogliptin Benzoate , Alogliptin Benzoate supplier , purchase Alogliptin Benzoate , Alogliptin Benzoate cost , Alogliptin Benzoate manufacturer , order Alogliptin Benzoate , high purity Alogliptin Benzoate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: